NCT05354544 is a Phase 1 clinical trial of Autologous adipose derived SVF in Vocal Fold Scars, sponsored by Shane A. Shapiro.

Who is sponsoring NCT05354544?

NCT05354544 is sponsored by Shane A. Shapiro.

What drugs are being tested in NCT05354544?

Interventions in NCT05354544: Autologous adipose derived SVF.

What condition does NCT05354544 study?

NCT05354544 studies Vocal Fold Scars.

Is NCT05354544 still recruiting?

NCT05354544 is currently terminated. Last updated 19 December 2024.

Last reviewed 2024-12-19 · How we verify

NCT05354544

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Autologous Stromal Vascular Fraction in Subjects with Vocal Fold Scar

Terminated Phase 1 Last updated 19 December 2024

What this trial tests

Phase 1 trial testing Autologous adipose derived SVF in Vocal Fold Scars in 2 participants. Terminated before completion.

Timeline

1 August 2021

Primary endpoint
5 December 2024

5 December 2024

Quick facts

Lead sponsor	Shane A. Shapiro
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	1 August 2021
Primary completion	5 December 2024
Estimated completion	5 December 2024
Sites	1 location across United States

Drugs / interventions tested

Autologous adipose derived SVF — full drug profile →

Conditions studied

Vocal Fold Scars — all drugs for Vocal Fold Scars →

Sponsor

Shane A. Shapiro — full company profile →

Who can join

Adults 18 to 80, any sex, with Vocal Fold Scars. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to assess if autologous Stromal Vascular Fraction (SVF) taken from the stomach or hips can help heal vocal fold scars.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tissue Engineering as a Promising Treatment for Glottic Insufficiency: A Review on Biomolecules and Cell-Laden Hydrogel.
Ng WC, Lokanathan Y, Baki MM, Fauzi MB, et al · · 2022 · cited 3× · PMID 36551838 · DOI 10.3390/biomedicines10123082

Verify or expand the search:

Other Shane A. Shapiro trials

Trials by the same sponsor.

NCT04826224 — CAM Procedure With BMAC for Shoulder OA · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05354544 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shane A. Shapiro
Last refreshed: 19 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05354544.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing